1. Home
  2. HGLB vs NYXH Comparison

HGLB vs NYXH Comparison

Compare HGLB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Highland Global Allocation Fund

HGLB

Highland Global Allocation Fund

HOLD

Current Price

$8.18

Market Cap

178.6M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$2.94

Market Cap

152.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HGLB
NYXH
Founded
N/A
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.6M
152.8M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
HGLB
NYXH
Price
$8.18
$2.94
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
67.1K
53.7K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$214.32
Revenue Next Year
N/A
$124.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.23
$2.76
52 Week High
$10.64
$8.64

Technical Indicators

Market Signals
Indicator
HGLB
NYXH
Relative Strength Index (RSI) 52.12 49.34
Support Level $8.21 $2.76
Resistance Level $9.06 $3.32
Average True Range (ATR) 0.32 0.18
MACD 0.06 0.05
Stochastic Oscillator 81.05 59.09

Price Performance

Historical Comparison
HGLB
NYXH

About HGLB Highland Global Allocation Fund

Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: